Black Hawk Acquisition Corporation
BKHA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BKHA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BKHA
Black Hawk Acquisition Corporation (BKHA) is a blank-check company formed to pursue a business combination, currently targeting a merger with Vesicor Therapeutics, Inc., a pre-clinical biotech developing AI-driven peptide therapeutics.
Key risk: Business combination failure
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of May 31, 2026.
Black Hawk Acquisition Corporation (BKHA) is a blank-check company formed to pursue a business combination, currently targeting a merger with Vesicor Therapeutics, Inc., a pre-clinical biotech developing AI-driven peptide therapeutics.
- Formed as a special purpose acquisition company (SPAC) to merge with one or more target businesses [sec_mda · as of 2026-03-06].
- Entered into a Business Combination Agreement with Vesicor Therapeutics, Inc. on April 26, 2025 [sec_mda · as of 2026-03-06].
- Vesicor's platform leverages Yotta-ML, an AI trained on a proprietary 10^24 protein/peptide sequence dataset, to discover agonists/antagonists for targets like GLP-1, GIP-1, and checkpoint receptors [sec · filed 2026-03-17].
- Cash and equivalents of $0.0M as of 2026-05-31, with shareholders' equity of -$3.8M and no debt [latest reported financials].
- Management includes a co-founder of Aikium and a scientist with prior involvement in Avastin development and the first siRNA drug taken to clinic [sec · filed 2026-03-17].
What works
- Vesicor's AI platform (Yotta-ML) is trained on a massive proprietary dataset of 10^24 sequences, potentially enabling novel therapeutic discovery for validated targets [sec · filed 2026-03-17].
- Management has deep industry experience, including prior roles in the discovery of the VEGF pathway and development of Avastin and the first siRNA drug [sec · filed 2026-03-17].
- The proposed business combination targets a pre-clinical biotech with a focus on enhancing blockbuster drug classes (GLP-1, checkpoint inhibitors, ADCs), which are large and growing markets [sec · filed 2026-03-17].
What to weigh
- As a SPAC with no current operations, the company has no revenue and a negative shareholders' equity of -$3.8M as of 2026-05-31 [latest reported financials].
- The business combination is subject to significant risks, including potential termination, legal proceedings, and financing uncertainties [sec · filed 2025-04-29].
- Vesicor's assets are pre-clinical, meaning they have not yet entered human trials and face high development and regulatory risks [sec · filed 2026-03-17].
- The company has a limited cash position ($0.0M as of 2026-05-31), which may require additional financing to complete the combination or fund operations post-merger [latest reported financials].
From the filings
Quoted directly from source documents.
Vesicor's AI platform uses a proprietary 10^24 sequence dataset
“Yotta-ML, the world's first proprietary 10^24 protein/peptide sequence structured data-set trained, drug discovery AI platform”
SEC filings · March 17, 2026
The company entered into a Business Combination Agreement with Vesicor on April 26, 2025
“On April 26, 2025, we entered into a Business Combination Agreement with Vesicor Therapeutics, Inc. and BH Merger Sub, Inc.”
SEC MD&A · March 6, 2026
Risks & what to watch (4)›
Key risks
- Business combination failure — The merger with Vesicor may be terminated due to events, legal proceedings, or inability to complete [sec · filed 2025-04-29].
- Pre-clinical stage assets — Vesicor's therapeutics are pre-clinical, with no approved products and high development risk [sec · filed 2026-03-17].
- No revenue and negative equity — The company has no operating revenue and negative shareholders' equity of -$3.8M as of 2026-05-31 [latest reported financials].
- Financing and dilution risk — Cash position is $0.0M as of 2026-05-31, requiring additional capital that may dilute shareholders [latest reported financials].
What to watch
- Completion of the business combination with Vesicor Therapeutics, including shareholder approval and regulatory clearances [sec · filed 2025-04-29].
- Any updates on Vesicor's pre-clinical pipeline, particularly AI-driven candidates targeting GLP-1 and checkpoint receptors [sec · filed 2026-03-17].
- Financial condition post-merger, including cash runway and any additional financing rounds [latest reported financials].
- Management's ability to execute on the combined company's strategy given the pre-clinical stage and competitive landscape [sec · filed 2026-03-17].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Black Hawk Acquisition Corporation through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Black Hawk Acquisition Corporation facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
0.3 months
OCF -$237K · Net income $89K
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
20
Total value held
$17.9M
| Holder | Shares | Value |
|---|---|---|
| mizuho securities usa llc | 373,800 | $4.3M |
| wolverine asset management llc | 340,810 | $3.9M |
| berkley w r corp | 309,134 | $3.6M |
| boothbay fund management, llc | 120,000 | $1.4M |
| meteora capital, llc | 89,000 | $1.0M |
| d. e. shaw & co., inc. | 75,000 | $866K |
| warberg asset management llc | 72,323 | $841K |
| crossingbridge advisors, llc | 53,024 | $615K |
| polar asset management partners inc. | 39,100 | $453K |
| rlh capital llc | 29,448 | $342K |
Showing top 10 of 20 institutional holders of Black Hawk Acquisition Corporation. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 0.0%
- Days to cover
- 0.2
- Shares short
- 106
- Daily short volume (Aug 28, 2026)
- 50.1%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BKHA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Black Hawk Acquisition Corporation?
Black Hawk Acquisition Corporation (BKHA) is a blank-check company formed to pursue a business combination, currently targeting a merger with Vesicor Therapeutics, Inc., a pre-clinical biotech developing AI-driven peptide therapeutics.
Who is the CEO of Black Hawk Acquisition Corporation?
Mr. Kent Louis Kaufman is the chief executive officer of Black Hawk Acquisition Corporation (BKHA).
Where is Black Hawk Acquisition Corporation headquartered?
Black Hawk Acquisition Corporation (BKHA) is headquartered in Danville, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.